Literature DB >> 30120410

Oxytocin attenuates phencyclidine hyperactivity and increases social interaction and nucleus accumben dopamine release in rats.

Shivali Kohli1, Madeleine V King1, Stuart Williams1, Adele Edwards1, Theresa M Ballard2, Lucinda J Steward2, Daniella Alberati2, Kevin C F Fone3.   

Abstract

The pituitary neuropeptide oxytocin promotes social behavior, and is a potential adjunct therapy for social deficits in schizophrenia and autism. Oxytocin may mediate pro-social effects by modulating monoamine release in limbic and cortical areas, which was investigated herein using in vivo microdialysis, after establishing a dose that did not produce accompanying sedative or thermoregulatory effects that could concomitantly influence behavior. The effects of oxytocin (0.03-0.3 mg/kg subcutaneous) on locomotor activity, core body temperature, and social behavior (social interaction and ultrasonic vocalizations) were examined in adult male Lister-hooded rats, using selective antagonists to determine the role of oxytocin and vasopressin V1a receptors. Dopamine and serotonin efflux in the prefrontal cortex and nucleus accumbens of conscious rats were assessed using microdialysis. 0.3 mg/kg oxytocin modestly reduced activity and caused hypothermia but only the latter was attenuated by the V1a receptor antagonist, SR49059 (1 mg/kg intraperitoneal). Oxytocin at 0.1 mg/kg, which did not alter activity and had little effect on temperature, significantly attenuated phencyclidine-induced hyperactivity and increased social interaction between unfamiliar rats without altering the number or pattern of ultrasonic vocalizations. In the same rats, oxytocin (0.1 mg/kg) selectively elevated dopamine overflow in the nucleus accumbens, but not prefrontal cortex, without influencing serotonin efflux. Systemic oxytocin administration attenuated phencyclidine-induced hyperactivity and increased pro-social behavior without decreasing core body temperature and selectively enhanced nucleus accumbens dopamine release, consistent with activation of mesocorticolimbic circuits regulating associative/reward behavior being involved. This highlights the therapeutic potential of oxytocin to treat social behavioral deficits seen in psychiatric disorders such as schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30120410      PMCID: PMC6300530          DOI: 10.1038/s41386-018-0171-0

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  85 in total

1.  Oral oxytocin antagonists.

Authors:  Alan D Borthwick
Journal:  J Med Chem       Date:  2010-09-23       Impact factor: 7.446

Review 2.  Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward.

Authors:  Ellen R Bradley; Joshua D Woolley
Journal:  Neurosci Biobehav Rev       Date:  2017-05-12       Impact factor: 8.989

3.  Oxytocin and vasopressin release within the supraoptic and paraventricular nuclei of pregnant, parturient and lactating rats: a microdialysis study.

Authors:  I Neumann; J A Russell; R Landgraf
Journal:  Neuroscience       Date:  1993-03       Impact factor: 3.590

Review 4.  Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine.

Authors:  Andreas Meyer-Lindenberg; Gregor Domes; Peter Kirsch; Markus Heinrichs
Journal:  Nat Rev Neurosci       Date:  2011-08-19       Impact factor: 34.870

5.  Induction of maternal behavior in virgin rats after intracerebroventricular administration of oxytocin.

Authors:  C A Pedersen; A J Prange
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

6.  A gender-specific mechanism for pair bonding: oxytocin and partner preference formation in monogamous voles.

Authors:  T R Insel; T J Hulihan
Journal:  Behav Neurosci       Date:  1995-08       Impact factor: 1.912

Review 7.  Assembling the Puzzle: Pathways of Oxytocin Signaling in the Brain.

Authors:  Valery Grinevich; H Sophie Knobloch-Bollmann; Marina Eliava; Marta Busnelli; Bice Chini
Journal:  Biol Psychiatry       Date:  2015-04-25       Impact factor: 13.382

Review 8.  Oxytocin in the socioemotional brain: implications for psychiatric disorders.

Authors:  Peter Kirsch
Journal:  Dialogues Clin Neurosci       Date:  2015-12       Impact factor: 5.986

Review 9.  From Autism to Eating Disorders and More: The Role of Oxytocin in Neuropsychiatric Disorders.

Authors:  Adele Romano; Bianca Tempesta; Maria Vittoria Micioni Di Bonaventura; Silvana Gaetani
Journal:  Front Neurosci       Date:  2016-01-12       Impact factor: 4.677

10.  Age and sex differences in oxytocin and vasopressin V1a receptor binding densities in the rat brain: focus on the social decision-making network.

Authors:  Caroline J W Smith; Max L Poehlmann; Sara Li; Aarane M Ratnaseelan; Remco Bredewold; Alexa H Veenema
Journal:  Brain Struct Funct       Date:  2016-07-07       Impact factor: 3.270

View more
  12 in total

1.  Oxytocin increases eye gaze in schizophrenia.

Authors:  Ellen R Bradley; Alison Seitz; Andrea N Niles; Katherine P Rankin; Daniel H Mathalon; Aoife O'Donovan; Joshua D Woolley
Journal:  Schizophr Res       Date:  2019-08-12       Impact factor: 4.939

2.  The vagus nerve mediates the suppressing effects of peripherally administered oxytocin on methamphetamine self-administration and seeking in rats.

Authors:  Nicholas A Everett; Anita J Turner; Priscila A Costa; Sarah J Baracz; Jennifer L Cornish
Journal:  Neuropsychopharmacology       Date:  2020-05-25       Impact factor: 7.853

Review 3.  Oxytocin in Schizophrenia: Pathophysiology and Implications for Future Treatment.

Authors:  Kah Kheng Goh; Chun-Hsin Chen; Hsien-Yuan Lane
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923

4.  1MeTIQ and olanzapine, despite their neurochemical impact, did not ameliorate performance in fear conditioning and social interaction tests in an MK-801 rat model of schizophrenia.

Authors:  Magdalena Białoń; Agnieszka Chocyk; Iwona Majcher-Maślanka; Marcelina Żarnowska; Krzysztof Michalski; Lucyna Antkiewicz-Michaluk; Agnieszka Wąsik
Journal:  Pharmacol Rep       Date:  2021-01-06       Impact factor: 3.024

Review 5.  The Role of Central Serotonin Neurons and 5-HT Heteroreceptor Complexes in the Pathophysiology of Depression: A Historical Perspective and Future Prospects.

Authors:  Dasiel O Borroto-Escuela; Patrizia Ambrogini; Barbara Chruścicka; Maria Lindskog; Minerva Crespo-Ramirez; Juan C Hernández-Mondragón; Miguel Perez de la Mora; Harriët Schellekens; Kjell Fuxe
Journal:  Int J Mol Sci       Date:  2021-02-15       Impact factor: 5.923

Review 6.  Overcoming Depression with 5-HT2A Receptor Ligands.

Authors:  Agata Zięba; Piotr Stępnicki; Dariusz Matosiuk; Agnieszka A Kaczor
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

Review 7.  Role of Oxytocin and Vasopressin in Neuropsychiatric Disorders: Therapeutic Potential of Agonists and Antagonists.

Authors:  Valeska Cid-Jofré; Macarena Moreno; Miguel Reyes-Parada; Georgina M Renard
Journal:  Int J Mol Sci       Date:  2021-11-08       Impact factor: 5.923

8.  Oxytocin promotes social proximity and decreases vigilance in groups of African lions.

Authors:  Jessica C Burkhart; Saumya Gupta; Natalia Borrego; Sarah R Heilbronner; Craig Packer
Journal:  iScience       Date:  2022-03-30

Review 9.  G Protein-Coupled Receptor Heteromers as Putative Pharmacotherapeutic Targets in Autism.

Authors:  Jon DelaCuesta-Barrutia; Olga Peñagarikano; Amaia M Erdozain
Journal:  Front Cell Neurosci       Date:  2020-10-30       Impact factor: 5.505

10.  Blocking mu-opioid receptors inhibits social bonding in rituals.

Authors:  S J Charles; M Farias; V van Mulukom; A Saraswati; S Dein; F Watts; R I M Dunbar
Journal:  Biol Lett       Date:  2020-10-14       Impact factor: 3.703

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.